




Instance: composition-en-2a5eb21f13292133a1b42432d323ff12
InstanceOf: CompositionUvEpi
Title: "Composition for busulfan Package Leaflet"
Description:  "Composition for busulfan Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp09f69b028a70bf3ad03748302a299de9)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - busulfan"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet:</p>
<ol>
<li>What Busulfan Fresenius Kabi is and what it is used for </li>
<li>What you need to know before you use Busulfan Fresenius Kabi </li>
<li>How to use Busulfan Fresenius Kabi  </li>
<li>Possible side effects </li>
<li>How to store Busulfan Fresenius Kabi </li>
<li>Contents of the pack and other information </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What busulfan is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What busulfan is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>This medicine contains the active substance busulfan, which belongs to a group of medicines called 
alkylating agents. Busulfan Fresenius Kabi destroys the original bone marrow before the transplant. </p>
<p>Busulfan Fresenius Kabi is used in adults, new-born infants, children and adolescents as a treatment 
prior to transplantation. </p>
<p>In adults Busulfan Fresenius Kabi is used in combination with cyclophosphamide or fludarabine. </p>
<p>In new-born infants, children and adolescents, this medicine is used in combination with 
cyclophosphamide or melphalan. </p>
<p>You will receive this preparative medicine before receiving a transplant of either bone marrow or 
haematopoietic progenitor cell. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take busulfan"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take busulfan"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not use Busulfan Fresenius Kabi:</p>
<ul>
<li>if you are allergic to busulfan or any of the other ingredients of this medicine listed in section 6. - if you are pregnant, or think you may be pregnant. </li>
</ul>
<p>Warnings and precautions 
Busulfan Fresenius Kabi is a potent cytotoxic medicine that results in profound decrease of blood cells. 
At the recommended dose, this is the desired effect. Therefore careful monitoring will be performed.  </p>
<p>It is possible that use of Busulfan Fresenius Kabi may increase the risk of suffering another 
malignancy in the future. You should tell your doctor:</p>
<ul>
<li>if you have a liver, kidney, heart or lung problem, </li>
<li>if you have a history of seizures, </li>
<li>if you are currently taking other medicines. </li>
</ul>
<p>Cases of formation of blood clots in the small blood vessels may appear after hematopoietic cell 
transplantation (HCT) with high-dose of your treatment in combination with other medicines. 
Other medicines and Busulfan Fresenius Kabi 
Tell your doctor if you are taking or have recently taken or might take any other medicines, including 
medicines obtained without a prescription. Busulfan Fresenius Kabi may interact with other medicines. </p>
<p>Particular caution should be taken if you use itraconazol and metronidazole (used for certain 
types of infections) or ketobemidone (used to treat pain) or deferasirox (a medicine used to 
remove excess iron from your body), because this may increase the side-effects. </p>
<p>The use of paracetamol during the 72 hours prior to or with Busulfan Fresenius Kabi administration 
should be used with caution. </p>
<p>Pregnancy, breast-feeding and fertility 
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask 
your doctor before you receive treatment with Busulfan Fresenius Kabi. Women must not be 
pregnant during treatment with Busulfan Fresenius Kabi and up to 6 months after treatment. 
Women must stop breast-feeding before starting their treatment with Busulfan Fresenius Kabi. </p>
<p>Adequate contraceptive precautions should be used when either partner is receiving Busulfan Fresenius 
Kabi. </p>
<p>It may no longer be possible for you to achieve a pregnancy (infertility) after treatment with Busulfan 
Fresenius Kabi. If you are concerned about having children, you should discuss this with your doctor 
before treatment. Busulfan Fresenius Kabi can also produce symptoms of menopause and in 
pre-adolescent girls it can prevent the onset of puberty. </p>
<p>Men treated with Busulfan Fresenius Kabi are advised not to father child during and up to 6 months after 
treatment. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take busulfan"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take busulfan"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dose and administration 
The dose of busulfan will be calculated according to your body weight. </p>
<p>In adults: 
Busulfan Fresenius Kabi in combination with cyclophosphamide:</p>
<ul>
<li>The recommended dose of Busulfan Fresenius Kabi is 0.8 mg/kg  </li>
</ul>
<p>Each infusion will last 2 hours </p>
<p>Busulfan will be administered every 6 hours during 4 consecutive days prior to transplant. </p>
<p>Busulfan Fresenius Kabi in combination with fludarabine </p>
<p>The recommended dose of busulfan is 3.2 mg/kg </p>
<p>Each infusion will last 3 hours </p>
<p>Busulfan will be administered once daily during 2 or 3 consecutive days prior to transplant. </p>
<p>In new-born infants, children and adolescents (0 to 17 years): 
The recommended dose of Busulfan Fresenius Kabi in combination with cyclophosphamide or 
melphalan is based on your body weight varying between 0.8 and 1.2 mg/kg. </p>
<p>Medicines before you receive Busulfan Fresenius Kabi: 
Before receiving Busulfan Fresenius Kabi, you will be medicated with 
- anticonvulsive medicines to prevent seizures (phenytoin or benzodiazepines) and 
- antiemetic medicines to prevent vomiting. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, Busulfan Fresenius Kabi can cause side effects, although not everybody gets them. </p>
<p>Serious side effects: 
The most serious side effects of busulfan therapy or the transplant procedure may include decrease in 
circulating blood cell counts (intended effect of the medicine to prepare you for your transplant 
infusion), infection, liver disorders including blocking of a liver vein, graft versus host disease (the graft 
attacks your body) and pulmonary complications. Contact your doctor immediately if you get any of the 
following symptoms. Your doctor will monitor your blood counts and liver enzymes regularly to detect 
and manage these events. </p>
<p>Other side effects may include: 
Very common (may affect more than 1 in 10 people): 
Blood: decrease of blood circulating cells (red and white) and platelets. Infections.  Nervous system: 
insomnia, anxiety, dizziness, and depression. Nutrition: loss of appetite, decrease in magnesium, 
calcium, potassium, phosphate, albumine in blood, and increase in blood sugar. Cardiac: increase in 
heart rate, increase or decrease of blood pressure, vasodilatation (a state of increased calibre of the 
blood vessels), and blood clots. Respiratory: shortness of breath, nasal secretion (rhinitis), sore throat, 
cough, hiccup, nosebleeds, abnormal breath sounds. Gastro-intestinal: nausea, inflammation of the 
mucosa of the mouth, vomiting, abdominal pain, diarrhoea, constipation, heart burn, anus discomfort, 
liquid in the abdomen. Hepatic: enlarged liver, jaundice, blocking of a liver vein. Skin: rash, itching, 
loss of hairs. Muscle and bone: back, muscle and joint pain. Renal: increase in creatinine elimination, 
discomfort in urination, and decrease in urine output and bloody urine. General: fever, headache, 
weakness, chills, pain, allergic reaction, oedema, general pain or inflammation at injection site, chest 
pain, inflammation of the mucosa. Investigations: elevated liver enzymes and weight increased. </p>
<p>Common (may affect up to 1 in 10 people): 
Nervous system: confusion, nervous system disorders. Nutrition: low blood sodium. Cardiac: 
changes and abnormalities in heart rhythm, fluid retention or inflammation around the heart, decrease 
heart output. Respiratory: increase in breath rhythm, respiratory failure, alveolar haemorrhages, 
asthma, collapse of small portions of the lung, fluid around the lung. Gastro-intestinal: inflammation 
of the mucosa of oesophagus, paralysis of the gut, vomiting blood. Skin: Skin colour disorder, redness 
of the skin, skin desquamation. Renal: increase in the amount of nitrogen components in the blood 
stream, moderate renal insufficiency, renal disorder. </p>
<p>Uncommon (may affect up to 1 in 100 people): 
Nervous system: delirium, nervousness, hallucination, agitation, abnormal brain function, cerebral 
haemorrhage, and seizure. Cardiac: clotting of femoral artery, extra heart beats, decrease in heart rate, 
diffuse leak of fluid from the capillaries (small blood vessels). Respiratory: decrease in blood oxygen. 
Gastro-intestinal: bleeding in the stomach and/or the gut. </p>
<p>Not known (frequency cannot be estimated from the available data) 
Sex glands dysfunction 
Lens disorders including clouding of the lens of the eye (cataract), and blurred vision (corneal 
thinning) 
Menopausal symptoms and female infertility. 
Brain abscess, Inflammation of the skin, generalised infection. 
Liver disorders. 
Increase of lactate dehydrogenase in the blood. 
Increase of uric acid and urea in the blood. 
Incomplete development of teeth </p>
<p>Reporting of side effects 
If you get any side effects, talk to your doctor. This includes any possible side effects not listed in this 
leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. 
By reporting side effects you can help provide more information on the safety of this medicine. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store busulfan"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store busulfan"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children. 
Do not use this medicine after the expiry date which is stated on the vial label and the carton after EXP. </p>
<p>Unopened vials: 
Store in a refrigerator (2 C - 8 C). 
Diluted solution: 
Chemical and physical in-use stability after dilution in glucose 5% or sodium chloride 9 mg/ml (0.9%) 
solution for injection has been demonstrated for 8 hours (including infusion time) after dilution when 
stored at 25 C   2 C or 12 hours after dilution when stored at 2 C-8 C followed by 3 hours stored at 
25 C   2 C (including infusion time). Do not freeze. </p>
<p>Do not throw away any medicine via wastewater or household waste. Ask your pharmacist how 
to throw away medicine you no longer use. These measures will help protect environment. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Busulfan Fresenius Kabi contains 
- The active substance is busulfan. One ml of concentrate contains 6 mg busulfan (60 mg in the 
vial). After dilution: one ml of solution contains approximately 0.5 mg of busulfan. 
- The other ingredients are dimethylacetamide and macrogol 400. What Busulfan Fresenius Kabi looks like and contents of the pack 
Busulfan Fresenius Kabi consists of a concentrate for solution for infusion. When diluted Busulfan 
Fresenius Kabi is a clear colourless viscous solution.  </p>
<p>Busulfan Fresenius Kabi is supplied in colourless glass vials, each vial containing 60 mg of busulfan. 
Each vial is sleeved with shrinkable plastic film. </p>
<p>Each vial contains 10 ml of concentrate. </p>
<p>Pack size 
1 pack containing 8 vials (8 cartons of 1 vial). </p>
<p>Marketing Authorisation Holder  </p>
<p>Fresenius Kabi Deutschland GmbH 
Else-Kr ner-Stra e 1, 
61352 Bad Homburg v.d.H he 
Germany </p>
<p>Manufacturer 
Fresenius Kabi Deutschland GmbH 
Pfingstweide 61169 Friedberg 
Germany  </p>
<p>For any information about this medicine, please contact the Marketing Authorisation Holder </p>
<p>This leaflet was last revised in {MM/YYYY} </p>
<p>Other sources of information 
Detailed information on this product is available on the website of European Medicinal 
Agency http://www.ema/europa.eu 
---------------------------------------------------------------------------------------------------------------- The following information is intended for healthcare professionals only </p>
<p>PREPARATION GUIDE </p>
<p>Busulfan Fresenius Kabi 6 mg/ml concentrate for solution for infusion 
Busulfan </p>
<p>Read this guide prior to the preparation and administration of Busulfan Fresenius Kabi. </p>
<ol>
<li>PRESENTATION </li>
</ol>
<p>Busulfan Fresenius Kabi is supplied as a clear colourless viscous solution in 10 ml clear, colourless 
glass vials (type I). Busulfan Fresenius Kabi must be diluted prior to administration. </p>
<ol>
<li>RECOMMENDATION FOR SAFE HANDLING </li>
</ol>
<p>Procedures for proper handling and disposal of anticancer medicinal products should be considered. </p>
<p>All transfer procedures require strict adherence to aseptic techniques, preferably employing a vertical 
laminar flow safety hood. </p>
<p>As with other cytotoxic compounds, caution should be exercised in handling and preparing the busulfan 
solution:</p>
<ul>
<li>The use of gloves and protective clothing is recommended. </li>
<li>If the concentrate or diluted busulfan solution contacts the skin or mucosa, wash them thoroughly 
with water immediately. </li>
</ul>
<p>Calculation of the quantity of Busulfan Fresenius Kabi to be diluted and of the diluent </p>
<p>Busulfan Fresenius Kabi must be diluted prior to use with either sodium chloride 9 mg/ml (0.9%) 
solution for injection or glucose solution for injection 5%. </p>
<p>The quantity of the diluent must be 10 times the volume of Busulfan Fresenius Kabi ensuring the final 
concentration of busulfan remains at approximately 0.5 mg/ml. </p>
<p>The amount of Busulfan Fresenius Kabi and diluent to be administered would be calculated as follows: 
for a patient with a Y kg body weight: </p>
<ul>
<li>Quantity of Busulfan Fresenius Kabi: </li>
</ul>
<p>Y (kg) x D (mg/kg)  </p>
<p>= A ml of Busulfan Fresenius Kabi to be diluted </p>
<p>6 (mg/ml) </p>
<p>Y: body weight of the patient in kg 
D: dose of busulfan (see SPC section 4.2) </p>
<ul>
<li>Quantity of diluent: </li>
</ul>
<p>(A ml Busulfan Fresenius Kabi) x (10) = B ml of diluent </p>
<p>To prepare the final solution for infusion, add (A) ml of Busulfan Fresenius Kabi to (B) ml of diluent 
(sodium chloride 9 mg/ml (0.9%) solution for injection or glucose solution for injection 5%). </p>
<p>Preparation of the solution for infusion </p>
<p>Busulfan Fresenius Kabi must be prepared by a healthcare professional using sterile transfer techniques.<br />
* Using a non polycarbonate syringe fitted with a needle:</p>
<ul>
<li>
<p>the calculated volume of Busulfan Fresenius Kabi must be removed from the vial. </p>
</li>
<li>
<p>the contents of the syringe must be dispensed into an intravenous bag (or syringe) which 
already contains the calculated amount of the selected diluent. Busulfan Fresenius Kabi must 
always be added to the diluent, not the diluent to the Busulfan Fresenius Kabi. Busulfan 
Fresenius Kabi must not be put into an intravenous bag that does not contain sodium chloride 
9 mg/ml (0.9%) solution for injection or glucose solution for injection 5%. </p>
</li>
<li>
<p>The diluted solution must be mixed thoroughly by inverting several times. </p>
</li>
</ul>
<p>After dilution, 1 ml of solution for infusion contains 0.5 mg of busulfan. </p>
<p>Diluted Busulfan Fresenius Kabi is a clear colourless solution </p>
<p>Instructions for use 
Prior to and following each infusion, flush the indwelling catheter line with approximately 5 ml of 
sodium chloride 9 mg/ml (0.9%) solution for injection or glucose (5%) solution for injection. </p>
<p>The residual medicinal product must not be flushed in the administration tubing as rapid infusion of 
busulfan has not been tested and is not recommended. </p>
<p>The entire prescribed busulfan dose should be delivered over two or three hours depending on the 
conditioning regimen. </p>
<p>Small volumes may be administered over 2 hours using electric syringes. In that case infusion sets with 
minimal priming space should be used (i.e 0.3-0.6 ml), primed with medicinal product solution prior to 
beginning the actual busulfan infusion and then flushed with sodium chloride 9 mg/ml (0.9%) solution 
for injection or glucose (5%) solution for injection. </p>
<p>Busulfan must not be infused concomitantly with another intravenous solution.  </p>
<p>Due to incompatibility, do not use infusion components containing polycarbonate with busulfan. </p>
<p>For single use only. Only a clear solution without particles should be used. </p>
<p>Storage conditions 
Unopened vials: 
Store in a refrigerator (2 C   8 C). </p>
<p>Diluted solution: 
Chemical and physical in-use stability after dilution in glucose 5% or sodium chloride 9 mg/ml (0.9%) 
solution for injection has been demonstrated for 8 hours (including infusion time) after dilution when 
stored at 25 C   2 C or 12 hours after dilution when stored at 2 C-8 C followed by 3 hours stored at 
25 C   2 C (including infusion time). </p>
<p>From a microbiological point of view, the product should be used immediately after dilution. 
If not used immediately, in-use storage times and conditions are the responsibility of the user and would 
normally not be longer than the above-mentioned conditions when dilution has taken place in controlled 
and validated aseptic conditions. 
Do not freeze the diluted solution. </p>
<ol>
<li>PROCEDURE FOR PROPER DISPOSAL </li>
</ol>
<p>Any unused medicinal product or waste should be disposed of in accordance with local requirements for 
cytotoxic medicinal products. </p>         </div>"""      



Instance: composition-da-2a5eb21f13292133a1b42432d323ff12
InstanceOf: CompositionUvEpi
Title: "Composition for busulfan Package Leaflet"
Description:  "Composition for busulfan Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp09f69b028a70bf3ad03748302a299de9)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - busulfan"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen 
1. Virkning og anvendelse<br />
2. Det skal du vide, før du begynder at bruge Busulfan Fresenius Kabi 
3. Sådan skal du bruge Busulfan Fresenius Kabi 
4. Bivirkninger 
5. Opbevaring 
6. Pakningsstørrelser og yderligere oplysninger </p>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What busulfan is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What busulfan is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Denne medicin indeholder det aktive stof busulfan, som hører til en lægemiddelgruppe, der kaldes 
alkylerende midler. Busulfan Fresenius Kabi ødelægger din egen knoglemarv før transplantationen. </p>
<p>Til voksne, spædbørn, børn og unge anvendes  Busulfan Fresenius Kabi som behandling før 
transplantation. </p>
<p>Til voksne anvendes Busulfan Fresenius Kabi i kombination med cyclophosphamid eller fludarabin.  </p>
<p>Til spædbørn, børn og unge anvendes denne medicin i kombination med cyclophosphamid eller 
melphalan. </p>
<p>Du vil få denne medicin som forbehandling, før du skal have foretaget en transplantation med enten 
knoglemarv eller hæmatopoietiske progenitorceller. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take busulfan"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take busulfan"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Brug ikke Busulfan Fresenius Kabi:</p>
<ul>
<li>hvis du er allergisk over for busulfan eller et af de øvrige indholdsstoffer i denne medicin (angivet 
i afsnit 6). </li>
<li>hvis du er gravid eller har mistanke om, at du kan være gravid. </li>
</ul>
<p>Advarsler og forsigtighedsregler 
Busulfan Fresenius Kabi er en kraftig cellegift (et cytostatikum), som medfører et voldsomt fald i antallet 
af blodlegemer. I den anbefalede dosis er det den ønskede virkning. Behandlingen vil derfor finde sted 
under omhyggelig overvågning.  </p>
<p>Det er muligt, at anvendelse af busulfan øger risikoen for at få en anden ondartet sygdom i fremtiden. 
Du skal fortælle din læge:</p>
<h2>- hvis du har lever-, nyre-, hjerte- eller lungeproblemer.</h2>
<h2>hvis du tidligere har haft krampeanfald.</h2>
<p>hvis du tager andre lægemidler. </p>
<p>Der kan forekomme tilfælde af blodpropdannelse i de små blodkar efter hæmatopoietisk 
celletransplantation (HCT), hvis du får højdosis-behandling i kombination med andre 
lægemidler. </p>
<p>Brug af anden medicin sammen med Busulfan Fresenius Kabi 
Fortæl det altid til lægen, hvis du bruger anden medicin eller har gjort det for nylig. Dette gælder også 
medicin, som ikke er købt på recept. Busulfan Fresenius Kabi kan reagere med andre lægemidler.  </p>
<p>Der skal udvises særlig forsigtighed, hvis du anvender itraconazol og metronidazol (anvendes til visse 
infektioner) eller ketobemidon (anvendes til at behandle smerter) eller deferasirox (et 
lægemiddel, der anvendes til at fjerne overskydende jern fra kroppen), fordi det kan forøge 
bivirkningerne. </p>
<p>Brug af paracetamol i op til 72 timer før eller samtidig med indgivelse af Busulfan Fresenius Kabi skal 
ske med forsigtighed.  </p>
<p>Graviditet, amning og frugtbarhed 
Hvis du er gravid eller ammer, har mistanke om, at du er gravid, eller planlægger at blive gravid, skal  du 
spørge din læge til råds, før du bruger Busulfan Fresenius Kabi. Kvinder skal undgå at blive gravide 
under behandling med Busulfan Fresenius Kabi og op til 6 måneder efter endt behandling. </p>
<p>Kvinder skal stoppe med at amme, inden behandlingen med Busulfan Fresenius Kabi påbegyndes. </p>
<p>Hvis den ene part i et forhold får Busulfan Fresenius Kabi, skal parret anvende sikker prævention. </p>
<p>Det kan være, at det ikke længere er muligt for dig at blive gravid (ufrugtbarhed) efter 
behandling med Busulfan Fresenius Kabi. Hvis du spekulerer på at få børn, skal du tale med din læge før 
behandlingen. Busulfan Fresenius Kabi kan også give symptomer på overgangsalder, og hos præ-
teenagepiger kan det forhindre, at puberteten indtræder. </p>
<p>Mænd, der behandles med Busulfan Fresenius Kabi, rådes til ikke at få børn under og i op til 6 måneder 
efter behandlingen.  </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take busulfan"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take busulfan"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dosis og indgivelse 
Dosis af Busulfan Fresenius Kabi beregnes ud fra din legemsvægt.  </p>
<p>Til voksne: 
Busulfan Fresenius Kabi i kombination med cyclophosphamid. </p>
<p>− 
Den anbefalede dosis af Busulfan Fresenius Kabi er 0,8 mg/kg . 
− 
Hver infusion varer 2 timer 
− 
Busulfan Fresenius Kabi gives hver 6. time 4 dage i træk forud for transplantationen </p>
<p>Busulfan Fresenius Kabi i kombination med fludarabin 
− 
Den anbefalede dosis af Busulfan Fresenius Kabi er 3,2 mg/kg 
− 
Hver infusion varer 3 timer 
− 
Busulfan Fresenius Kabi gives én gang dagligt 2 eller 3 dage i træk forud for transplantationen </p>
<p>Til spædbørn, børn og unge (0 til 17 år): 
Den anbefalede dosis Busulfan Fresenius Kabi i kombination med cyclophosphamid eller melphalan 
afhænger af din legemsvægt og varierer fra mellem 0,8 og 1,2 mg/kg. 
Medicin før du får Busulfan Fresenius Kabi: 
Før du får Busulfan Fresenius Kabi, vil du blive behandlet med 
-<br />
krampestillende lægemidler for at forebygge krampeanfald (phenytoin eller benzodiazepiner) og 
-<br />
lægemidler mod kvalme for at forebygge opkastning. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som al anden medicin give bivirkninger, men ikke alle får bivirkninger. </p>
<p>Alvorlige bivirkninger: 
De alvorligste bivirkninger ved behandlingen med busulfan eller selve transplantationen kan være et fald i 
antallet af blodlegemer i blodcirkulationen (ønsket effekt af lægemidlet for at forberede dig til 
transplantationsinfusionen), betændelse, leversygdomme herunder blokering af en vene i leveren, 
graft-versus-host-disease (hvor donorcellerne angriber din krop) og lungekomplikationer. Kontakt din 
læge omgående, hvis du oplever nogle af ovenstående symptomer. Din læge vil løbende kontrollere dine 
blodværdier og leverenzymer for at opdage og behandle disse bivirkninger. </p>
<p>Andre bivirkninger kan indbefatte: 
Meget almindelige (kan påvirke mere end 1 ud af 10 patienter): 
Blodet: nedsat antal cirkulerende blodlegemer (røde og hvide) og blodplader.<br />
Infektioner 
Nervesystemet: søvnløshed, angst, svimmelhed og depression.<br />
Ernæring: appetitløshed, nedsat indhold af magnesium, calcium, kalium, fosfat og albumin i blodet samt 
stigning i blodsukker. 
Hjerte: øget hjertefrekvens, stigning eller fald af blodtrykket, vasodilatation (en 
tilstand, hvor blodkarrene udvides) og blodpropper.<br />
Åndedræt: åndenød, snue (rhinitis), ondt i halsen, hoste, hikke, næseblod, unormale åndedrætslyde.<br />
Mave-tarm: kvalme, betændelse af mundslimhinden, opkastning, mavesmerter, diarre, forstoppelse, 
halsbrand, ubehag ved endetarmsåbningen, væske i maven.<br />
Lever: forstørret lever, gulsot, blokering af vene i leveren.<br />
Hud: udslæt, kløe, hårtab.<br />
Muskler og knogler: smerter i ryg, muskler og led.<br />
Nyrer: øgning i kreatininudskillelsen, ubehag ved vandladning, nedsættelse af urinmængden og blod i 
urinen. 
Generelt: feber, hovedpine, slaphed, kulderystelser, smerter, allergiske reaktioner, væskeansamlinger, 
generelle smerter eller betændelse ved injektionsstedet, brystsmerter, infektion i slimhinder. 
Undersøgelser: forhøjede leverenzymer og vægtøgning. </p>
<p>Almindelige (kan påvirke op til 1 ud af 10 patienter): 
Nervesystemet: forvirring (konfus), sygdomme i nervesystemet.<br />
Ernæring: lavt natriumindhold i blodet.<br />
Hjerte: ændret og unormal hjerterytme, tilbageholdelse af væske eller betændelse omkring hjertet, nedsat 
hjertefunktion.<br />
Åndedræt: hurtigere åndedræt, åndedrætssvigt, blødning i lungerne (alveolerne), astma, sammenfald 
af små dele i lungerne, væske omkring lungerne.<br />
Mave-tarm: betændelse i spiserørets slimhinde, lammelse af tarmen, opkastning af blod.<br />
Hud: ændret hudfarve, rødmen, hudafskalning.<br />
Nyrer: øgning i mængden af kvælstofkomponenter i blodbanen, moderat nedsat nyrefunktion, 
nyresygdom.  </p>
<p>Ikke almindelige (kan påvirke op til 1 ud af 100 patienter): 
Nervesystemet: uklarhed, forvirring og desorientering, evt. hallucinationer og vrangforestillinger 
(delirium), nervøsitet, hallucinationer, rastløs uro, unormal hjernefunktion, hjerneblødning og kramper.<br />
Hjerte: blodpropper i femoralarterien (pulsåren, der fører blodet til benene og fødderne), ekstra 
hjerteslag, fald i hjertefrekvensen, diffus udsivning af væske fra kapillærerne (de små blodkar). 
Åndedræt: nedsat mængde ilt i blodet. 
Mave-tarm: mave- og/eller tarmblødning. </p>
<p>Ukendt hyppighed (kan ikke estimeres ud fra forhåndenværende data) 
Nedsat funktion af kønskirtlerne. 
Sygdomme i øjets linse, herunder uklarhed af øjets linse (grå stær) og sløret syn (hornhinden bliver 
tyndere). 
Symptomer på overgangsalder og ufrugtbarhed hos kvinder. 
Byld i hjernen, betændelseslignende tilstand i huden, generaliseret infektion. 
Leversygdomme. 
Forhøjet laktatdehydrogenase i blodet. 
Forhøjet urinsyre og urinstof i blodet. 
Ufuldstændig udvikling af tænder. </p>
<p>Indberetning af bivirkninger 
Hvis du oplever bivirkninger, bør du tale med din læge, sygeplejerske eller apoteket. Dette gælder også 
mulige bivirkninger, som ikke er medtaget i denne indlægsseddel. Du eller dine pårørende kan også 
indberette bivirkninger direkte til Lægemiddelstyrelsen via det nationale rapporteringssystem anført i 
Appendiks V. Ved at indrapportere bivirkninger kan du hjælpe med at fremskaffe mere information om 
sikkerheden af dette lægemiddel. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store busulfan"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store busulfan"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opbevar lægemidlet utilgængeligt for børn. </p>
<p>Brug ikke lægemidlet efter den udløbsdato, der står på hætteglassets etiket og æsken efter EXP.  </p>
<p>Uåbnede hætteglas 
Opbevares i køleskab (2°C – 8°C). </p>
<p>Fortyndet opløsning: 
Det er påvist, at den kemiske og fysiske i brug-stabilitet er 8 timer (inklusive infusionstid) efter 
fortynding med 5 % glucose injektionsvæske eller med 9 mg/ml (0,9 %) natriumchlorid injektionsvæske, 
hvis opbevaring sker ved 25°C±2°C eller 12 timer efter fortynding, hvis opbevaring sker ved 2°C - 8°C 
efterfulgt af 3 timers opbevaring ved 25°C±2°C (inklusive infusionstid). Må ikke nedfryses. </p>
<p>Spørg på apoteket, hvordan du skal bortskaffe medicinrester. Af hensyn til miljøet må du ikke smide 
medicinrester i afløbet eller skraldespanden. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Busulfan Fresenius Kabi indeholder:</p>
<ul>
<li>Aktivt stof: busulfan. En ml koncentrat indeholder 6 mg busulfan (60 mg i et hætteglas). Efter 
fortynding: En ml opløsning indeholder cirka 0,5 mg busulfan. </li>
<li>Øvrige indholdsstoffer: dimethylacetamid og macrogol 400. Udseende og pakningsstørrelser 
Busulfan Fresenius Kabi er et koncentrat til infusionsvæske, opløsning. Efter fortynding er Busulfan 
Fresenius Kabi en klar farveløs viskøs opløsning.  </li>
</ul>
<p>Busulfan Fresenius Kabi leveres i farveløse hætteglas. Hvert hætteglas indeholder 60 mg busulfan. Hvert 
hætteglas er forsynet med en film af krympeplast.  </p>
<p>Hvert hætteglas indeholder 10 ml koncentrat. </p>
<p>Pakningsstørrelse </p>
<p>1 pakning indeholdende 8 hætteglas (8 æsker á 1 hætteglas).  </p>
<p>Indehaver af markedsføringstilladelsen<br />
Fresenius Kabi Deutschland GmbH 
Else-Kröner-Straße 1, 
61352 Bad Homburg v.d.Höhe 
Tyskland </p>
<p>Fremstiller 
Fresenius Kabi Deutschland GmbH 
Pfingstweide 61169 Friedberg 
Tyskland  </p>
<p>Hvis du ønsker yderligere oplysninger om dette lægemiddel, skal du henvende dig til indehaveren af 
markedsføringstilladelsen. </p>
<p>Denne indlægsseddel blev senest ændret  </p>
<p>Du kan finde yderligere oplysninger om dette lægemiddel på Det Europæiske Lægemiddelagenturs 
hjemmeside http://www.ema.europa.eu/.  </p>
<p>&lt;----------------------------------------------------------------------------------------------------------------------------&gt; 
Nedenstående oplysninger er til læger og sundhedspersonale: </p>
<p>VEJLEDNING I TILBEREDNING </p>
<p>Busulfan Fresenius Kabi 6 mg/ml koncentrat til infusionsvæske, opløsning 
Busulfan </p>
<p>Læs denne vejledning før tilberedning og indgift af Busulfan Fresenius Kabi. </p>
<ol>
<li>
<p>PAKNING 
Busulfan Fresenius Kabi leveres som klar farveløs viskøs opløsning i 10 ml klart farveløst hætteglas (type 
1). Busulfan Fresenius Kabi skal fortyndes før indgift.  </p>
</li>
<li>
<p>ANBEFALET FREMGANGSMÅDE FOR SIKKER HÅNDTERING 
Der bør fastlægges procedurer for korrekt håndtering og bortskaffelse af cytotoksiske lægemidler. </p>
</li>
</ol>
<p>Alle procedurer for overførsel kræver nøje overholdelse af aseptiske forhold, idet overførsel fortrinsvis 
skal udføres i en vertikal LAF-bænk. </p>
<p>Som for andre cytostatika skal der udvises forsigtighed ved håndtering og tilberedning af 
busulfanopløsningen:</p>
<ul>
<li>Det anbefales at anvende beskyttelseshandsker og -tøj. </li>
<li>Hvis koncentratet eller den fortyndede busulfanopløsning kommer i kontakt med hud eller 
slimhinder, skal de berørte områder omgående skylles med rigeligt vand. </li>
</ul>
<p>Beregning af mængden af Busulfan Fresenius Kabi, der skal fortyndes, og af fortyndingsvæsken </p>
<p>Busulfan Fresenius Kabi skal fortyndes før brug med enten 9 mg/ml (0,9 %) natriumchlorid 
injektionsvæske eller 5 % glucose injektionsvæske. </p>
<p>For at sikre, at den endelige koncentration af busulfan er ca. 0,5 mg/ml, skal mængden af 
fortyndingsvæske være 10 gange volumenet af Busulfan Fresenius Kabi. For eksempel: </p>
<p>Mængden af Busulfan Fresenius Kabi og fortyndingsvæske, som skal administreres, vil blive beregnet på 
følgende vis for en patient, som vejer Y kg:  </p>
<ul>
<li>Mængde Busulfan Fresenius Kabi: </li>
</ul>
<p>Y (kg) x D (mg/kg) = A ml Busulfan Fresenius Kabi, som skal fortyndes. 
6 (mg/ml) </p>
<p>Y: patientens legemsvægt i kg 
D: busulfandosis (se pkt.4.2) </p>
<ul>
<li>Mængde fortyndingsvæske: 
(A ml Busulfan Fresenius Kabi) x (10) = B ml fortyndingsvæske </li>
</ul>
<p>Til tilberedning af den endelige infusionsopløsning tilsættes (A) ml Busulfan Fresenius Kabi til (B) ml 
fortyndingsvæske (9 mg/ml (0,9 %) natriumchlorid injektionsvæske eller 5 % glucose injektionsvæske). </p>
<p>Fremstilling af infusionsopløsningen </p>
<ul>
<li>
<p>Busulfan Fresenius Kabi skal tilberedes af sundhedspersonale under anvendelse af steril 
overførselsmetode. 
Der anvendes en sprøjte, der ikke er af polycarbonat, isat kanyle:</p>
</li>
<li>
<p>den beregnede mængde Busulfan Fresenius Kabi tages ud af hætteglasset. </p>
</li>
<li>
<p>sprøjtens indhold skal overføres til en infusionspose (eller -sprøjte), som allerede indeholder den 
beregnede mængde af den valgte fortyndingsvæske. Busulfan Fresenius Kabi tilsættes altid til 
fortyndingsvæsken, ikke fortyndingsvæsken til Busulfan Fresenius Kabi. Busulfan Fresenius 
Kabi må kun overføres til en infusionspose, som indeholder 9 mg/ml (0,9 %) natriumchlorid 
injektionsvæske eller 5 % glucose injektionsvæske. </p>
</li>
<li>
<p>Den fortyndede opløsning skal blandes grundigt ved at vende op og ned på posen flere gange. </p>
</li>
</ul>
<p>Efter fortynding: 1 ml infusionsopløsning indeholder 0,5 mg busulfan. </p>
<p>Efter fortynding er Busulfan Fresenius Kabi en klar, farveløs opløsning. </p>
<p>Vejledning i brug 
Før og efter hver infusion gennemskylles det indlagte kateter og slange med ca. 5 ml 9 mg/ml (0,9 %) 
natriumchlorid injektionsvæske eller 5 % glucose injektionsvæske. </p>
<p>Evt. lægemiddelrest i droppet må ikke skylles ind i venen, da hurtig infusion af busulfan ikke er 
afprøvet og derfor ikke anbefales. </p>
<p>Hele den ordinerede busulfandosis skal indgives i løbet af 2 eller 3 timer, afhængigt af det 
konditionerende regime. </p>
<p>Små mængder kan administreres i løbet af 2 timer med anvendelse af elektriske sprøjter. I det tilfælde 
skal der anvendes infusionssæt med minimal volumen (dvs. 0,3-0,6 ml), som primes med 
lægemiddelopløsningen, inden den egentlige infusion med busulfan iværksættes, og derefter skylles 
med 9 mg/ml (0,9 %) natriumchlorid injektionsvæske eller 5 % glucose injektionsvæske. </p>
<p>Busulfan må ikke infunderes samtidig med en anden intravenøs opløsning. </p>
<p>På grund af uforligelighed må der ikke anvendes infusionskomponenter, der indeholder polycarbonat, 
sammen med busulfan.<br />
Kun til engangsbrug. Opløsningen skal være klar og uden partikler. </p>
<p>Opbevaringsbetingelser 
Uåbnede hætteglas: 
Opbevares i køleskab (2°C – 8°C) </p>
<p>Fortyndet opløsning: 
Kemisk og fysisk i-brug stabilitet efter fortynding med 5 % glucose- eller 
9 mg/ml (0,9 %) natriumchlorid injektionsvæske er påvist i 8 timer (inkl. infusionstid) efter fortynding, 
hvis opbevaring sker ved 25°C±2°C eller 12 timer efter fortynding, hvis opbevaring sker ved 2°C - 8°C 
efterfulgt af 3 timers opbevaring ved 25°C±2°C (inkl. infusionstid). </p>
<p>Ud fra et mikrobiologisk synspunkt bør produktet anvendes straks efter fortynding. 
Hvis det ikke anvendes straks, er brugeren ansvarlig for opbevaringstid og -betingelser før brug og vil 
almindeligvis ikke være længere end de ovenfor anførte betingelser, når fortyndingen har fundet sted 
under kontrollerede og validerede aseptiske forhold.  </p>
<p>Den fortyndede opløsning må ikke fryses.  </p>
<ol>
<li>PROCEDURE FOR KORREKT BORTSKAFFELSE 
Ikke anvendt lægemiddel samt affald heraf skal bortskaffes i henhold til lokale retningslinjer for 
cytotoksiske lægemidler. </li>
</ol>         </div>"""      





                    
Instance: bundlepackageleaflet-en-2a5eb21f13292133a1b42432d323ff12
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for busulfan Package Leaflet for language en"
Description: "ePI document Bundle for busulfan Package Leaflet for language en"
Usage: #example




* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-2a5eb21f13292133a1b42432d323ff12"
* entry[0].resource = composition-en-2a5eb21f13292133a1b42432d323ff12

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp2a5eb21f13292133a1b42432d323ff12"
* entry[=].resource = mp2a5eb21f13292133a1b42432d323ff12
                            
                    
Instance: bundlepackageleaflet-da-2a5eb21f13292133a1b42432d323ff12
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for busulfan Package Leaflet for language da"
Description: "ePI document Bundle for busulfan Package Leaflet for language da"
Usage: #example




* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-2a5eb21f13292133a1b42432d323ff12"
* entry[0].resource = composition-da-2a5eb21f13292133a1b42432d323ff12

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp2a5eb21f13292133a1b42432d323ff12"
* entry[=].resource = mp2a5eb21f13292133a1b42432d323ff12
                            
                    



Instance: mp2a5eb21f13292133a1b42432d323ff12
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product busulfan"
Description: "busulfan"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "EU/1/14/951/001"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"


* indication = "Busulfan followed by cyclophosphamide (BuCy2) is indicated as conditioning treatment prior to"


* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"


* name
  * productName = "busulfan"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#DK "DK"
    * jurisdiction = urn:iso:std:iso:3166#DK "DK"
    * language = urn:ietf:bcp:47#en  "en"




RuleSet: 2a5eb21f13292133a1b42432d323ff12ListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "busulfan"

* status = #current
* mode = #working

* title = "List of all ePIs associated with busulfan"

* subject = Reference(mp09f69b028a70bf3ad03748302a299de9)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#busulfan "busulfan"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-2a5eb21f13292133a1b42432d323ff12) // busulfan en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-2a5eb21f13292133a1b42432d323ff12) // busulfan da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-2a5eb21f13292133a1b42432d323ff12
InstanceOf: List

* insert 2a5eb21f13292133a1b42432d323ff12ListRuleset
    